Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. Why are those important?

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Drug Discovery World

MAY 16, 2023

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. NewBiologix is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies.

Production 52

Production Gene Therapy Gene Bioinformatics 52

Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. Why are those important?

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Drug Discovery World

OCTOBER 20, 2023

GenomeFrontier partners with BioCina on CAR-T therapy CDMO BioCina and GenomeFrontier Therapeutics will partner on the development of virus-free CAR-T products for cancer treatment. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions. Industry 4.0’

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

DECEMBER 13, 2023

Modern is making significant strides in advancing its mRNA technology and diversifying its product portfolio to address a broad spectrum of medical conditions. Dynavax boasts two successful commercial products in its portfolio. Notably, R&D expenditures for the second quarter of 2023 surged by 62 percent to reach $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111